Advertisement

Topics

Families of Spinal Muscular Atrophy Company Profile

11:26 EST 22nd November 2017 | BioPortfolio

Families of Spinal Muscular Atrophy (FSMA) is dedicated to creating a treatment and cure by: funding and advancing a comprehensive research program; supporting SMA families through networking, information and services; improving care for all SMA patients; educating health professionals and the public about SMA; enlisting government support for SMA; embracing all touched by SMA in a caring community. FSMA's vision is a world where Spinal Muscular Atrophy is treatable and curable.


News Articles [772 Associated News Articles listed on BioPortfolio]

Spinal Muscular Atrophy SMA Epidemiology Insights to 2025 [Report Updated: 31072017] Prices from USD $2950

DelveInsight's Spinal Muscular Atrophy SMA Epidemiology Forecast, 2025 provides an overview of the epidemiology trends of Spinal Muscular Atrophy SMA in seven major markets US, France, Germany, Italy,...

Gene Therapy, New Drug, Spinraza, Battle Rare Spinal Muscular Atrophy in Kids

WEDNESDAY, Nov. 1, 2017 -- Babies born with a previously untreatable degenerative nerve disease now have two fresh sources of hope for their future. Two innovative new therapies for spinal muscular at...

Monthly News Roundup - December 2016

Biogen’s Spinraza Approved for Spinal Muscular Atrophy The U.S. Food and Drug Administration (FDA) has cleared Biogen's Spinraza (nusinersen), the first drug for spinal muscular atrophy (SMA), a ra...

Spinal Muscular Atrophy SMA Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 31072017] Prices from USD $5750

DelveInsight's Spinal Muscular Atrophy SMA Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Spinal Muscular Atrophy...

PTC Therapeutics Release: Spinal Muscular Atrophy Program Advances Into Pivotal Study In SMA Patients

SOUTH PLAINFIELD, N.J., Oct. 12, 2017 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Fo...

Biogen Unveils More Study Data for Spinraza at SMA 2017

ArticleSpinal muscular atrophy is a genetic condition characterized by loss of motor neurons in the spinal cord and lower brain stem inducing severe and progressive muscular atrophy and weakness.

Treatment for Spinal Muscular Atrophy

In a randomized, double-blind, sham-controlled study of infants with spinal muscular atrophy (SMA) type 1, nusinersen treatment led to significant improvement in motor milestones and survival without ...

Spinal Muscular Atrophy SMA Pipeline Insight, 2017 [Report Updated: 31072017] Prices from USD $1250

DelveInsight's, Spinal Muscular Atrophy SMAPipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Spinal Muscular Atrophy SMA. The r...

PubMed Articles [2004 Associated PubMed Articles listed on BioPortfolio]

Symptom management and psychological support for families are the cornerstones of end-of-life care for children with spinal muscular atrophy type 1.

This study described end-of-life care for children affected by spinal muscular atrophy type 1 (SMA1), which is characterised by progressive muscle weakness and develops in the first six months of life...

Upper limb functional assessment scale for children with Duchenne muscular dystrophy and Spinal muscular atrophy.

Duchenne muscular dystrophy (DMD) and Spinal muscular atrophy (SMA) causes significant disability and progressive functional impairment. Readily available instruments that assess functionality, especi...

Swallowing markers in spinal and bulbar muscular atrophy.

We examined the characteristics of dysphagia in spinal and bulbar muscular atrophy, a hereditary neuromuscular disease causing weakness of limb, facial, and oropharyngeal muscles via a videofluoroscop...

Natural History of Infantile-Onset Spinal Muscular Atrophy.

Infantile-onset spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, typically resulting in death prior to age 2. Clinical trials in this population require an understan...

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug...

Clinical Trials [2812 Associated Clinical Trials listed on BioPortfolio]

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

The primary objective of this study is to demonstrate a pharmacodynamic effect of CK-2127107 on measures of skeletal muscle function or fatigability in patients with Spinal Muscular Atroph...

French Registry of Patients With Infantile-onset Spinal Muscular Atrophy

IO-SMA-Registry is a prospective, longitudinal and observational study which objective is to collect prospectively information on longevity, psychomotor development and respiratory functio...

A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy

The purpose of this study is to evaluate the safety of olesoxime in participants with spinal muscular atrophy, focusing on the nature, frequency, and severity of adverse events, as well as...

Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy (SMA) is neurodegenerative disease of anterior horn cells of spinal cord and represents the second more frequent pathology in childhood. According to the age of ...

Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development

Spinal muscular atrophy (SMA) is the leading genetic cause of death of infants. Strong preclinical evidence suggests that effective therapy must be delivered as early as possible to preven...

Companies [863 Associated Companies listed on BioPortfolio]

Families of Spinal Muscular Atrophy

Families of Spinal Muscular Atrophy (FSMA) is dedicated to creating a treatment and cure by: funding and advancing a comprehensive research program; supporting SMA families through networking, informa...

Spinal Muscular Atrophy Foundation

Retrophin, LLC

Retrophin, LLC is a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is curr...

California Stem Cell, Inc.

California Stem Cell, Inc. is a privately held company focused on the manufacture of high-purity human cells for therapeutic development and screening applications. Since its foun...

PsychoGenics Inc.

PsychoGenics is a leader in preclinical behavioral neurobiology. The Company applies its behavioral expertise together with advances in robotics, computer vision, and informatics ...

More Information about "Families of Spinal Muscular Atrophy" on BioPortfolio

We have published hundreds of Families of Spinal Muscular Atrophy news stories on BioPortfolio along with dozens of Families of Spinal Muscular Atrophy Clinical Trials and PubMed Articles about Families of Spinal Muscular Atrophy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Families of Spinal Muscular Atrophy Companies in our database. You can also find out about relevant Families of Spinal Muscular Atrophy Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record